BD Viper™ Neutralization Pouch

The BD Onclarity™ HPV Assay is FDA and Health Canada approved for extended genotyping, offering the flexibility you need to adapt to changing screening guidelines and evolving patient management guidance.

FDA and Health Canada approved for all three screening paradigms:

In the post-vaccination era the prevalence of high-risk genotypes may change making it crucial to identify high-risk genotypes individually.

• Extended genotyping supports risk stratification and persistence monitoring to guide patient management^1-5
• Genotypes 16 and 18 account for 70% of invasive cancer worldwide, but their prevalence is declining as vaccination rates increase.^6-9
• Genotypes 31,33,58 have a CIN3+ risk similar to genotype 18, but 51,35,39,68,56,59,66 have a much lower risk.^10-11